Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma

por Brown, Ross, Suen, Hayley, Favaloro, James, Yang, Shihong, Ho, P. Joy, Gibson, John, Joshua, Douglas
Publicado 2012

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

por Quach, Hang, White, Darrell, Spencer, Andrew, Ho, P. Joy, Bhutani, Divaya, White, Mike, Inamdar, Sandeep, Morris, Chris, Ou, Ying, Gyger, Martin
Publicado 2017

Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study

por Ho, P. Joy, Hiwase, Devendra, Ramakrishna, Raj, Viiala, Nicholas, Solterbeck, Ann, Traficante, Robert, Zor, Evren, Gervasio, Othon L., High, Laura M., Ross, David M., Bowden, Donald K.
Publicado 2019

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

por McQuilten, Zoe, Wellard, Cameron, Moore, Elizabeth, Augustson, Bradley, Bergin, Krystal, Blacklock, Hilary, Harrison, Simon, Ho, P. Joy, King, Tracy, Quach, Hang, Mollee, Peter, Rosengarten, Brian, Walker, Patricia, Wood, Erica, Spencer, Andrew
Publicado 2022

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

por Kalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Ho, P Joy, Mollee, Peter, D’Rozario, James, Taylor, Kerry, Estell, Jane, Norton, Sam, Kemp, Roslyn, Mitchell, Andrew J., Reynolds, John, Kennedy, Nola, Quach, Hang, Spencer, Andrew
Publicado 2021

PB2698: MORE EFFICIENT DELIVERY OF HIGH-COST STANDARD-OF-CARE THERAPIES IN RELAPSED MULTIPLE MYELOMA USING REAL-TIME FEEDBACK OF PATIENT-REPORTED OUTCOME MEASURES: THE MY-PROMPT-2...

por Moore, Elizabeth, Harrison, Simon, Ho, P. Joy, Irving, Adam, King, Tracy, Mccaughan, Georgia, Mcquilten, Zoe, Mollee, Peter, Park, Susanna, Petrie, Dennis, Reynolds, John, Rutherford, Claudia, van Tonder, Tina, Wellard, Cameron, Wood, Erica, Spencer, Andrew
Publicado 2023

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

por Xu, Xu Steven, Dimopoulos, Meletios A., Sonneveld, Pieter, Ho, P. Joy, Belch, Andrew, Leiba, Merav, Capra, Marcelo, Gomez, David, Medvedova, Eva, Iida, Shinsuke, Min, Chang-Ki, Schecter, Jordan, Jansson, Richard, Zhang, Liping, Sun, Yu-Nien, Clemens, Pamela L.
Publicado 2018

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation

por Abadir, Edward, Gasiorowski, Robin E., Lai, Kaitao, Kupresanin, Fiona, Romano, Adelina, Silveira, Pablo A., Lo, Tsun‐Ho, Fromm, Phillip D., Kennerson, Marina L., Iland, Harry J., Ho, P. Joy, Hogarth, P. Mark, Bradstock, Kenneth, Hart, Derek N.J., Clark, Georgina J.
Publicado 2019

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

por Bahlis, Nizar J., Dimopoulos, Meletios A., White, Darrell J., Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Krevvata, Maria, Chiu, Christopher, Qin, Xiang, Okonkwo, Linda, Trivedi, Sonali, Ukropec, Jon, Qi, Ming, San-Miguel, Jesus
Publicado 2020

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

por Jaeger, Ulrich, Tam, Constantine S., Borchmann, Peter, McGuirk, Joseph P., Johansen, Marianne, Waller, Edmund K., Jaglowski, Samantha, Andreadis, Charalambos, Foley, Stephen R., Westin, Jason R., Fleury, Isabelle, Ho, P. Joy, Mielke, Stephan, Teshima, Takanori, Salles, Gilles, Schuster, Stephen J., He, Fiona, Maziarz, Richard T., Mayer, Sebastian, Makita, Shinichi, Kersten, Marie J., Ghosh, Monalisa, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Goto, Hideki, Colicino, Silvia, Agarwal, Abhijit, Lobetti-Bodoni, Chiara, Bishop, Michael R.
Publicado 2022

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

por Dimopoulos, Meletios A., San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Sutherland, Heather J., Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H. Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Wu, Kaida, Schecter, Jordan M., Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A. Kate, Khokhar, Nushmia Z., Avet-Loisea, Hervé, Usmani, Saad Z.
Publicado 2018